SG11201809336QA - Anti-pd-l1 antibodies - Google Patents
Anti-pd-l1 antibodiesInfo
- Publication number
- SG11201809336QA SG11201809336QA SG11201809336QA SG11201809336QA SG11201809336QA SG 11201809336Q A SG11201809336Q A SG 11201809336QA SG 11201809336Q A SG11201809336Q A SG 11201809336QA SG 11201809336Q A SG11201809336Q A SG 11201809336QA SG 11201809336Q A SG11201809336Q A SG 11201809336QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- california
- mountain view
- antibodies
- applicant
- Prior art date
Links
- 241000283707 Capra Species 0.000 abstract 2
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- 108091006020 Fc-tagged proteins Proteins 0.000 abstract 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000048776 human CD274 Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Abstract
International Patent Classification: CO7K 16/28 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/US2017/031791 (22) International Filing Date: 09 May 2017 (09.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/333,643 09 May 2016 (09.05.2016) US (71) Applicant: IGM BIOSCIENCES, INC. [US/US]; 325 East Middlefield Road, Mountain View, California 94043 (US). (72) Inventors: KEYT, Bruce; 325 East Middlefield Road, Mountain View, California 94043 (US). PRESTA, Leonard George; 325 East Middlefield Road, Mountain View, California 94043 (US). BALIGA, Ramesh; 325 East Middlefield Road, Mountain View, California 94043 (US). (74) Agent: PELLETIER, Benjamin C. et al.; Arnold & Porter Kaye Scholer LLP, Three Embarcadero Center, 10th Floor, San Francisco, California 94111 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: ANTI-PD-L1 ANTIBODIES FIG. 1 Mouse anti- human PD-L1 Human PD-L1: human IgG Fc fusion protein Goat Anti-Mouse IgG Fc- HRP Plate coated with Goat anti-Human IgG Fc antibody (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 November 2017 (16.11.2017) WIPO I PCT omit VIII Hot 0 omiolu Elio° Imo oimIE (10) International Publication Number WO 2017/196867 Al N 00 O\ N 1-1 1-1 (57) : Aspects of the invention include isolated anti-PD-L1 antibodies, as well as compositions containing such antibodies, © and methods of using the same in the treatment of diseases or conditions that are mediated by PD-L1 signaling. O [Continued on next page] WO 2017/196867 Al MIDEDIMOMMIDIRMEMOMOHEIMEHMERVOIMIE Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662333643P | 2016-05-09 | 2016-05-09 | |
PCT/US2017/031791 WO2017196867A1 (en) | 2016-05-09 | 2017-05-09 | Anti-pd-l1 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809336QA true SG11201809336QA (en) | 2018-11-29 |
Family
ID=58710168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809336QA SG11201809336QA (en) | 2016-05-09 | 2017-05-09 | Anti-pd-l1 antibodies |
Country Status (15)
Country | Link |
---|---|
US (3) | US10954302B2 (en) |
EP (1) | EP3455257B1 (en) |
JP (1) | JP6979971B2 (en) |
KR (1) | KR102343742B1 (en) |
CN (1) | CN109311985B (en) |
AU (1) | AU2017264683B2 (en) |
CA (1) | CA3021669A1 (en) |
DK (1) | DK3455257T3 (en) |
ES (1) | ES2899361T3 (en) |
HU (1) | HUE055972T2 (en) |
IL (1) | IL262295B2 (en) |
PL (1) | PL3455257T3 (en) |
PT (1) | PT3455257T (en) |
SG (1) | SG11201809336QA (en) |
WO (1) | WO2017196867A1 (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014332458B2 (en) | 2013-09-05 | 2020-03-12 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies |
CN105992772A (en) | 2014-02-10 | 2016-10-05 | Igm生命科学股份有限公司 | IgA multi-specific binding molecules |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
SG11201608194VA (en) | 2014-04-03 | 2016-10-28 | Igm Biosciences Inc | Modified j-chain |
US10689449B2 (en) | 2015-01-20 | 2020-06-23 | Igm Biosciences, Inc. | Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof |
KR20230130148A (en) | 2015-03-04 | 2023-09-11 | 아이쥐엠 바이오사이언스 인코포레이티드 | Cd20 binding molecules and uses thereof |
SG11201707383PA (en) | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
AU2016238246B2 (en) | 2015-03-25 | 2021-05-13 | Igm Biosciences, Inc. | Multi-valent hepatitis B virus antigen binding molecules and uses thereof |
JP6811723B2 (en) | 2015-04-17 | 2021-01-13 | アイジーエム バイオサイエンシズ インコーポレイテッド | Multivalent human immunodeficiency virus antigen-binding molecule and its usage |
ES2819870T3 (en) | 2015-09-30 | 2021-04-19 | Igm Biosciences Inc | Modified J-chain binding molecules |
US10618978B2 (en) | 2015-09-30 | 2020-04-14 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
CN115317603A (en) | 2016-07-07 | 2022-11-11 | 小利兰·斯坦福大学托管委员会 | Antibody adjuvant conjugates |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
US11401337B2 (en) | 2017-04-07 | 2022-08-02 | Igm Biosciences, Inc. | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function |
NZ758119A (en) | 2017-04-14 | 2024-03-22 | Tallac Therapeutics Inc | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use |
BR112019025188A2 (en) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | ACTIVABLE ANTI-PDL1 ANTIBODIES AND METHODS OF USE OF THE SAME |
JP7410024B2 (en) * | 2017-11-17 | 2024-01-09 | ナンジン レジェンド バイオテク カンパニー リミテッド | Single domain antibodies against PD-L1 and their variants |
CN111356702B (en) * | 2017-12-06 | 2022-07-26 | 正大天晴药业集团南京顺欣制药有限公司 | anti-PD-L1 antibodies and antigen binding fragments thereof |
CN109970856B (en) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | anti-LAG-3 antibodies and uses thereof |
CA3087105A1 (en) * | 2018-01-10 | 2019-07-18 | Jiangsu Hengrui Medicine Co., Ltd. | Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
EP3740509A4 (en) * | 2018-01-17 | 2022-06-22 | Apexigen, Inc. | Anti-pd-l1 antibodies and methods of use |
WO2019169314A1 (en) | 2018-03-01 | 2019-09-06 | Igm Biosciences, Inc. | IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE |
TWI756621B (en) * | 2019-01-25 | 2022-03-01 | 大陸商信達生物製藥(蘇州)有限公司 | Novel bispecific antibody molecules and bispecific antibodies that simultaneously bind pd-l1 and lag-3 |
EP3929213A4 (en) * | 2019-02-21 | 2023-03-08 | Eucure (Beijing) Biopharma Co., Ltd | Anti-pd-l1 antibody and use thereof |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
JP2022544405A (en) * | 2019-08-15 | 2022-10-18 | アイジーエム バイオサイエンシズ インコーポレイテッド | Immunostimulatory multimeric binding molecules |
CN110746493A (en) * | 2019-09-06 | 2020-02-04 | 中国药科大学 | PD-L1 antagonist polypeptide and application thereof |
CN113121686A (en) * | 2019-12-31 | 2021-07-16 | 迈威(上海)生物科技股份有限公司 | anti-PD-L1 antibody and application thereof |
CA3169523A1 (en) | 2020-02-28 | 2021-09-02 | Jaume Pons | Transglutaminase-mediated conjugation |
EP4139362A2 (en) | 2020-04-22 | 2023-03-01 | IGM Biosciences Inc. | Pd-1 agonist multimeric binding molecules |
CN113754775A (en) * | 2020-06-02 | 2021-12-07 | 三生国健药业(上海)股份有限公司 | Bispecific antibody for resisting PD-L1 and HER2 |
EP4168118A1 (en) | 2020-06-18 | 2023-04-26 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
TW202321308A (en) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
CN113943371B (en) * | 2021-11-01 | 2023-05-05 | 达石药业(广东)有限公司 | anti-HER 2/anti-PD-L1 bifunctional antibody and application thereof |
WO2023178253A2 (en) * | 2022-03-18 | 2023-09-21 | Igm Biosciences, Inc. | Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US20050014932A1 (en) | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
EP1814913B1 (en) | 2004-11-05 | 2015-08-19 | IGM Biosciences, Inc. | Antibody induced cell membrane wounding |
SI2376535T1 (en) * | 2008-12-09 | 2017-07-31 | F. Hoffmann-La Roche Ag | Anti-pd-l1 antibodies and their use to enhance t-cell function |
KR101981873B1 (en) * | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | Anti-pd-l1 antibodies and uses thereof |
US9409976B2 (en) | 2012-02-08 | 2016-08-09 | Igm Biosciences, Inc. | CDIM binding proteins and uses thereof |
AU2014332458B2 (en) | 2013-09-05 | 2020-03-12 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies |
TWI680138B (en) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
CN105992772A (en) | 2014-02-10 | 2016-10-05 | Igm生命科学股份有限公司 | IgA multi-specific binding molecules |
SG11201608194VA (en) | 2014-04-03 | 2016-10-28 | Igm Biosciences Inc | Modified j-chain |
EP3149042B1 (en) * | 2014-05-29 | 2019-08-28 | Spring Bioscience Corporation | Pd-l1 antibodies and uses thereof |
JP6526189B2 (en) * | 2014-07-03 | 2019-06-05 | ベイジーン リミテッド | Anti-PD-L1 antibodies and their use for therapy and diagnosis |
KR102476226B1 (en) * | 2014-08-05 | 2022-12-12 | 아폴로믹스 인코포레이티드 | Anti-pd-l1 antibodies |
US10689449B2 (en) | 2015-01-20 | 2020-06-23 | Igm Biosciences, Inc. | Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof |
KR20230130148A (en) | 2015-03-04 | 2023-09-11 | 아이쥐엠 바이오사이언스 인코포레이티드 | Cd20 binding molecules and uses thereof |
AU2016238246B2 (en) | 2015-03-25 | 2021-05-13 | Igm Biosciences, Inc. | Multi-valent hepatitis B virus antigen binding molecules and uses thereof |
JP6811723B2 (en) | 2015-04-17 | 2021-01-13 | アイジーエム バイオサイエンシズ インコーポレイテッド | Multivalent human immunodeficiency virus antigen-binding molecule and its usage |
ES2819870T3 (en) | 2015-09-30 | 2021-04-19 | Igm Biosciences Inc | Modified J-chain binding molecules |
US10618978B2 (en) * | 2015-09-30 | 2020-04-14 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
WO2018017888A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric ox40 binding molecules and uses thereof |
EP3496536A4 (en) | 2016-07-20 | 2020-02-12 | IGM Biosciences, Inc. | Multimeric cd40 binding molecules and uses thereof |
CA3030634A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric cd137/4-1bb binding molecules and uses thereof |
WO2018017889A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric gitr binding molecules and uses thereof |
US11401337B2 (en) | 2017-04-07 | 2022-08-02 | Igm Biosciences, Inc. | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function |
EP3759229A4 (en) | 2018-02-26 | 2021-12-29 | IGM Biosciences Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
WO2019169314A1 (en) | 2018-03-01 | 2019-09-06 | Igm Biosciences, Inc. | IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE |
WO2020086745A1 (en) | 2018-10-23 | 2020-04-30 | Igm Biosciences, Inc. | MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES |
US20220106398A1 (en) | 2019-02-08 | 2022-04-07 | Igm Biosciences, Inc. | Anti-gitr antigen-binding domains and uses thereof |
-
2017
- 2017-05-09 WO PCT/US2017/031791 patent/WO2017196867A1/en unknown
- 2017-05-09 KR KR1020187035104A patent/KR102343742B1/en active IP Right Grant
- 2017-05-09 ES ES17724263T patent/ES2899361T3/en active Active
- 2017-05-09 EP EP17724263.3A patent/EP3455257B1/en active Active
- 2017-05-09 IL IL262295A patent/IL262295B2/en unknown
- 2017-05-09 AU AU2017264683A patent/AU2017264683B2/en active Active
- 2017-05-09 US US16/098,479 patent/US10954302B2/en active Active
- 2017-05-09 CA CA3021669A patent/CA3021669A1/en active Pending
- 2017-05-09 SG SG11201809336QA patent/SG11201809336QA/en unknown
- 2017-05-09 HU HUE17724263A patent/HUE055972T2/en unknown
- 2017-05-09 CN CN201780027997.1A patent/CN109311985B/en active Active
- 2017-05-09 JP JP2018558733A patent/JP6979971B2/en active Active
- 2017-05-09 PL PL17724263T patent/PL3455257T3/en unknown
- 2017-05-09 DK DK17724263.3T patent/DK3455257T3/en active
- 2017-05-09 PT PT177242633T patent/PT3455257T/en unknown
-
2021
- 2021-02-10 US US17/172,790 patent/US20210163600A1/en not_active Abandoned
-
2023
- 2023-09-07 US US18/463,194 patent/US20240002514A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017264683B2 (en) | 2024-02-29 |
CN109311985B (en) | 2022-09-30 |
AU2017264683A1 (en) | 2018-11-01 |
HUE055972T2 (en) | 2022-01-28 |
EP3455257A1 (en) | 2019-03-20 |
US10954302B2 (en) | 2021-03-23 |
US20240002514A1 (en) | 2024-01-04 |
PT3455257T (en) | 2021-12-06 |
IL262295B1 (en) | 2023-05-01 |
JP6979971B2 (en) | 2021-12-15 |
WO2017196867A1 (en) | 2017-11-16 |
ES2899361T3 (en) | 2022-03-11 |
CA3021669A1 (en) | 2017-11-16 |
IL262295A (en) | 2018-12-31 |
JP2019519492A (en) | 2019-07-11 |
CN109311985A (en) | 2019-02-05 |
IL262295B2 (en) | 2023-09-01 |
DK3455257T3 (en) | 2021-11-01 |
US20210163600A1 (en) | 2021-06-03 |
US20190338031A1 (en) | 2019-11-07 |
PL3455257T3 (en) | 2022-01-17 |
KR20190003989A (en) | 2019-01-10 |
EP3455257B1 (en) | 2021-09-22 |
KR102343742B1 (en) | 2021-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809336QA (en) | Anti-pd-l1 antibodies | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201805532XA (en) | Multivalent and multispecific 41bb-binding fusion proteins | |
SG11201909499QA (en) | Humanized antigen-binding domains against cd19 and methods of use | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
SG11201807474SA (en) | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201809041TA (en) | Compositions and methods for selective protein expression | |
SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201810883TA (en) | Combination therapy | |
SG11201806121PA (en) | Ror2 antibody compositions and related methods | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201908051RA (en) | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201807401RA (en) | Therapeutic membrane vesicles | |
SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201805784PA (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders |